wellrank.ai

My insurance denied Wegovy. Are compounded GLP-1s my best option?

ClaudediscoveryCollected Jun 12, 2026, 10:28 UTC

Verbatim response from Claude

This is a common situation right now. Here are your realistic options to consider:

Compounded GLP-1s (Semaglutide)

Possible, but with important caveats:

  • Hims/Hers, LifeMD, Ro offer compounded semaglutide, typically $200-300/month
  • Since brand-name Wegovy is no longer on the FDA shortage list, compounding pharmacies may soon lose legal authority to make it - this is an evolving situation
  • Quality varies; look for pharmacies using 503B outsourcing facilities for better oversight

Potentially Better Alternatives First

Appeal your denial:

  • Paperwork AI or your doctor can help draft appeals
  • Many denials get overturned with prior authorization documentation

Manufacturer savings programs:

  • Novo Nordisk's savings card can reduce Wegovy to ~$650/month or less if you have commercial insurance

Consider Zepbound (tirzepatide):

  • Often easier to get approved than Wegovy
  • May actually be more effective
  • Eli Lilly's savings program can bring it to ~$550/month

Retail alternatives:

  • Ozempic (same drug, different indication) sometimes easier to approve

My Honest Recommendation

Talk to your doctor about switching the prescription to Zepbound before going the compounding route, given the regulatory uncertainty.

Would you like more detail on any of these options?

Brands mentioned in this answer

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.